SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending following the announcement of its largest-ever government contract, a $266 million deal with the U.S. Space Force for multiple suborbital launches. While investors are actively debating the company's long-term growth potential and recent expansion into defense and infrastructure, community sentiment is divided between those anticipating a major recovery and those concerned about the stock's sensitivity to broader sector volatility and the influence of SpaceX's recent price action.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing a pivotal week as its DMD therapy, deramiocel, heads to an FDA advisory committee review, with community sentiment heavily focused on securing a dual-indication label for both skeletal and cardiac benefits. Investors are closely watching for the release of briefing documents and the potential for a significant short squeeze, as high short interest clashes with strong advocacy from researchers and patients pushing for rapid approval.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a 1.5 million dollar grant from the National Science Foundation, which investors see as a confirmation of the company's status as a leader in government-backed quantum initiatives. The community is actively debating the stock's long-term potential versus concerns over high valuations and the impact of broader market volatility on the quantum sector.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging after argenx agreed to acquire the company in a significant all-cash deal, adding the FB102 antibody to its immunology pipeline. Investors are actively discussing the premium valuation provided by the acquisition and the potential future of the CD122-targeting platform within the broader immunology space.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant volatility following a mixed earnings report and conservative full-year guidance that triggered a sharp market reaction. Despite near-term concerns over revenue timing and management's messaging, the community remains intensely focused on the long-term growth potential of the Vevye dry eye franchise, upcoming retina product launches, and the potential for strategic M&A.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is currently trending as the market reacts to shifting geopolitical tensions between the U.S. and Iran, specifically community discussions surrounding the potential for ceasefire agreements and supply volatility. Investors are actively debating the impact of ongoing Middle East headlines on energy prices while monitoring the structural support levels and potential for leveraged decay in this oil-tracking instrument.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending due to significant leadership disruption following the departure of its CEO and market volatility surrounding its core CARVYKTI therapy. Community discourse is currently split between anxiety over competitive threats from bispecific combinations and optimism regarding the potential for an imminent buyout as institutional investors weigh the stock's oversold status.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a combination of lower-than-anticipated monthly sales data and uncertainty surrounding potential competition from AstraZeneca's rival therapeutic. While some community members view the sell-off as a temporary market overreaction or short-selling pressure ahead of upcoming J-code reimbursement catalysts, others are expressing concern over recent executive departures and the need for stronger leadership to drive commercial momentum.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as community members rally behind its potential as a leading Real-World Asset (RWA) project, citing institutional interest and upcoming regulatory milestones. While bullish investors are focused on long-term growth and the potential impact of legislative developments, others are actively debating the governance token structure and the necessity of future fee-based reward mechanisms.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing heightened volatility and active community debate following the FDA's acceptance of sNDA filings for its Duchenne muscular dystrophy therapies. While some investors see this as a de-risking catalyst pointing toward potential full approval, others remain skeptical, focusing on the company's long-term stock stagnation, competitive pressures, and ongoing criticism of management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
